U.S., July 30 -- ClinicalTrials.gov registry received information related to the study (NCT07090343) titled 'Semaglutide in Patients Undergoing Transcatether Aortic Valve Replacement' on July 11.
Brief Summary: This is a Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial evaluating the safety and efficacy of once-weekly semaglutide 2.4 mg in adult patients undergoing transcatheter aortic valve replacement (TAVR) for severe aortic stenosis (AS) who meet current clinical criteria for semaglutide treatment. A total of 826 participants will be randomized 1:1 to receive semaglutide or placebo as an add-on to standard-of-care, starting 3 months before TAVR and continuing for 24 months post-procedure. The primary ...